Guilin Sanjin Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2024: USD 105.17 M

Guilin Sanjin Pharmaceutical Co., Ltd. EBITDA is USD 105.17 M for the year ending December 31, 2024, a 12.98% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Guilin Sanjin Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2023 was USD 93.08 M, a 8.72% change year over year.
  • Guilin Sanjin Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2022 was USD 85.61 M, a -3.04% change year over year.
  • Guilin Sanjin Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2021 was USD 88.29 M, a 30.03% change year over year.
  • Guilin Sanjin Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2020 was USD 67.90 M, a -16.16% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)